188 related articles for article (PubMed ID: 33783712)
21. Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.
Bello OM; Druce M; Ansari E
BMJ Open Ophthalmol; 2024 Jun; 9(1):. PubMed ID: 38886120
[TBL] [Abstract][Full Text] [Related]
22. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
23. MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials.
Stan MN; Salvi M
Eur J Endocrinol; 2017 Feb; 176(2):R101-R109. PubMed ID: 27760790
[TBL] [Abstract][Full Text] [Related]
24. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
25. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab.
Karasek D; Cibickova L; Karhanova M; Kalitova J; Schovanek J; Frysak Z
Endokrynol Pol; 2017; 68(5):498-504. PubMed ID: 28660988
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: a systematic review and network meta-analysis.
Li H; Yang L; Song Y; Zhao X; Sun C; Zhang L; Zhao H; Pan Y
Acta Ophthalmol; 2022 Sep; 100(6):e1189-e1198. PubMed ID: 34918472
[TBL] [Abstract][Full Text] [Related]
27. Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment.
Du Pasquier-Fediaevsky L; Andrei S; Berche M; Leenhardt L; Héron E; Rivière S
Ocul Immunol Inflamm; 2019; 27(5):844-850. PubMed ID: 29652204
[No Abstract] [Full Text] [Related]
28. Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.
Adamidou F; Anagnostis P; Boboridis K; Manani C; Georgiou T; Veneti S; Kita M
Endocr J; 2018 Sep; 65(9):963-967. PubMed ID: 29937466
[TBL] [Abstract][Full Text] [Related]
29. Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy.
Bennedjaï A; Bouheraoua N; Gatfossé M; Dupasquier-Fediaevsky L; Errera MH; Tazartes M; Borderie V; Hennocq Q; Dellal A; Riviere S; Heron E; Fain O; Mekinian A
Ocul Immunol Inflamm; 2022 Feb; 30(2):500-505. PubMed ID: 32965148
[TBL] [Abstract][Full Text] [Related]
30. An infant case of Graves' disease with ophthalmopathy.
Kubo T; Shimizu J; Furujo M; Takeuchi A; Yoshioka-Iwaso H; Eguchi N; Fukuhara S; Koyama T; Kanadani T; Shiraga H; Oshima K
Endocr J; 2005 Oct; 52(5):647-50. PubMed ID: 16284447
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy.
Liu X; Guo H; Liu J; Shi B
Exp Ther Med; 2016 Aug; 12(2):1093-1096. PubMed ID: 27446325
[TBL] [Abstract][Full Text] [Related]
32. Proptosis is associated with thiol-disulfide in patients with Graves' ophthalmopathy.
Acibucu F; Öztürk DD; Kizildag C; Aslan MZ; Gulumsek E; Sumbul MS; Neselioglu S; Erel O; Sen S; Bankir M; Sumbul HE
Arch Endocrinol Metab; 2022 Apr; 66(2):191-197. PubMed ID: 35315985
[TBL] [Abstract][Full Text] [Related]
33. Common Immunosuppressive Monotherapy for Graves' Ophthalmopathy: A Meta-Analysis.
Mou P; Jiang LH; Zhang Y; Li YZ; Lou H; Zeng CC; Wang QH; Cheng JW; Wei RL
PLoS One; 2015; 10(10):e0139544. PubMed ID: 26469187
[TBL] [Abstract][Full Text] [Related]
34. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
[TBL] [Abstract][Full Text] [Related]
35. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study.
Erdei A; Paragh G; Kovacs P; Karanyi Z; Berenyi E; Galuska L; Lenkey A; Szabados L; Gyory F; Ujhelyi B; Berta A; Boda J; Berta E; Bodor M; Gazdag A; Nagy EV
Autoimmunity; 2014 Dec; 47(8):548-55. PubMed ID: 25039242
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Different Intravenous Glucocorticoid Regimens in the Treatment of Graves' Ophthalmopathy: A Meta-Analysis.
Chen J; Xu N; Sun H; Chen G
J Ophthalmol; 2021; 2021():9799274. PubMed ID: 34336262
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients.
Li LF; Xue JL; Guan L; Su FF; Wang H; Zhang DF
Front Endocrinol (Lausanne); 2023; 14():1140196. PubMed ID: 37025403
[TBL] [Abstract][Full Text] [Related]
38. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.
Mukasa K; Yoshimura Noh J; Kouzaki A; Ohye H; Kunii Y; Watanabe N; Yoshihara A; Matsumoto M; Suzuki M; Ito K
Endocr J; 2016; 63(2):151-7. PubMed ID: 26581710
[TBL] [Abstract][Full Text] [Related]
39. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.
Hegedüs L; Smith TJ; Douglas RS; Nielsen CH
Clin Endocrinol (Oxf); 2011 Jan; 74(1):1-8. PubMed ID: 20455896
[TBL] [Abstract][Full Text] [Related]
40. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
